Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis

Alemtuzumab (previously known as Campath(®)) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. Here we explore evidence for its efficacy and safety in relapsing-remitting multip...

Full description

Saved in:

Bibliographic Details
Published in:	Drug design, development and therapy Vol. 7; pp. 131 - 138
Main Authors:	Brown, William, Coles, Alasdair
Format:	Journal Article
Language:	English
Published:	New Zealand Dove Medical Press Limited 01.01.2013 Taylor & Francis Ltd Dove Press Dove Medical Press
Subjects:	Adjuvants, Immunologic - adverse effects Adjuvants, Immunologic - therapeutic use Alemtuzumab Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - immunology Antibodies, Monoclonal, Humanized - therapeutic use Antigens, CD - immunology Antigens, Neoplasm - immunology Atrophy Autoimmunity Brain Campath CD52 Antigen Clinical trials Drug therapy efficacy Glycoproteins - immunology Hemorrhage Humans Immunotherapy Interferon Interferon beta-1a Interferon-beta - adverse effects Interferon-beta - pharmacology Interferon-beta - therapeutic use Lymphocytes Lymphopenia Monoclonal antibodies Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - immunology Multiple Sclerosis, Relapsing-Remitting - physiopathology Patients Pharmaceutical research Purpura relapsing-remitting multiple sclerosis Review Therapy Thrombocytopenic purpura Thyroid Treatment Outcome relapsing–remitting multiple sclerosis alemtuzumab efficacy Campath
ISSN:	1177-8881, 1177-8881
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!